Effective Date:

Monday, February 02, 2015

Test Updates

Modified Date: 01/14/2015

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, February 02, 2015

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

12/19/2014: The following Acodes were removed, please refer to 12.29.14 IA DBU: 0801U, 0885U, 3110U, 3111U, 3113U, 3116U, 4127U, 4303U, 5113U, 5119U, 52092TI, 52092U, 52167TI, 52167U, 52264U, 52407U, 52448U, 52449U, 53092TI, 53092U, 53167TI, 53167U, 54334U, 55010U

01/14/2015: The CPT Codes were updated to the 2015 version.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
0070SP	Acetohexamide, Serum/Plasma								•
2302U	Aromatic Solvent Metabolites Panel 1, Urine		•	•	•	•		•	
0457U	Aromatic Solvents Panel, Urine								•
2626B	Bath Salts Panel, Blood			•		•			
2626SP	Bath Salts Panel, Serum/Plasma			•		•			
2626U	Bath Salts Panel, Urine			•	•	•			
3101U	Benzene Metabolites Panel, Urine			•					
52167TI	Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) Confirmation, Tissue (Forensic)	•		•	•			•	
53167TI	Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) Confirmation, Tissue (Forensic)	•		•		•		•	
52264U	Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) Confirmation (Qualitative), Urine (CSA)			•	•			•	
52167U	Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)				•			•	
53167U	Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)			•	•			•	
0801U	Buprenorphine and Metabolite - Total (Conjugated/Unconjugated), Urine			•	•			•	
5113U	Buprenorphine and Metabolite -Total (Conjugated/Unconjugated) Confirmation, Urine			•	•			•	
0885U	Butorphanol - Total (Conjugated/Unconjugated), Urine	•	•	•	•			•	
52019B	Chlorpropamide Confirmation, Blood (Forensic)	•		•	•			•	
53019B	Chlorpropamide Confirmation, Blood (Forensic)		•	•	•			•	
52019SP	Chlorpropamide Confirmation, Serum/Plasma (Forensic)		•		•			•	
53019SP	Chlorpropamide Confirmation, Serum/Plasma (Forensic)		•		•			•	
1220B	Chlorpropamide, Blood								•
1220SP	Chlorpropamide, Serum/Plasma		•		•			•	
1220U	Chlorpropamide, Urine								•
1350U	Cresols, Urine			•				•	
1439SP	Dantrolene, Serum/Plasma			•	•				
2029U	Ethylbenzene Exposure Biouptake, Urine		•	•		•		•	

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
54380B	Glimepiride Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic)	•		•	•			•	
54380SP	Glimepiride Confirmation (Drug Impaired Driving/DRE Toxicology), Serum/Plasma (Forensic)	•			•			•	
52438B	Glimepiride Confirmation, Blood (Forensic)	•		•	•			•	
52438SP	Glimepiride Confirmation, Serum/Plasma (Forensic)	•			•			•	
2158B	Glipizide, Blood								•
2158SP	Glipizide, Serum/Plasma		•	•	•		•	•	
2158U	Glipizide, Urine								•
2163B	Glyburide, Blood								•
2163SP	Glyburide, Serum/Plasma		•	•	•		•	•	
2306U	Hippuric Acid and Methylhippuric Acid, Urine		•	•	•	•		•	
2300U	Hippuric Acid, Urine		•	•	•			•	
4261B	Hypoglycemic Panel, Blood	•	•		•	•	•	•	
4261SP	Hypoglycemic Panel, Serum/Plasma	•	•		•	•	•	•	
54331B	Hypoglycemics Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic)		•	•	•		•	•	
54331SP	Hypoglycemics Confirmation (Drug Impaired Driving/DRE Toxicology), Serum/Plasma (Forensic)		•	•	•		•	•	
52405B	Hypoglycemics Confirmation, Blood (Forensic)		•	•	•		•	•	
52405SP	Hypoglycemics Confirmation, Serum/Plasma (Forensic)		•	•	•		•	•	
2416U	Inhalants Metabolites Panel, Urine		•	•	•	•		•	
2409U	Inhalants Panel, Urine (CSA)								•
2426U	Inhalants and Metabolites Panel, Urine								•
2505SP	Levetiracetam, Serum/Plasma				•				
2837SP	Methanol Poisoning Profile, Serum/Plasma			•					
2994U	Methylhippuric Acid, Urine								•
3110U	Nalbuphine - Total (Conjugated/Unconjugated), Urine	•	•	•	•			•	
5119U	Naloxone - Total (Conjugated/Unconjugated) Confirmation, Urine				•			•	
3113U	Naloxone - Total (Conjugated/Unconjugated) Screen, Urine			•	•				

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
3111U	Naloxone - Total (Conjugated/Unconjugated), Urine				•			•	
52449U	Naltrexone - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)				•			•	
3116U	Naltrexone and Metabolite - Total (Conjugated/Unconjugated), Urine				•			•	
0872U	Solvent Profile, Urine								•
4213U	Styrene Exposure Profile, Urine		•	•	•	•		•	
4127U	Suboxone® - Total, Urine			•	•			•	
52092TI	Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Tissue (Forensic)	•				•		•	
53092TI	Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Tissue (Forensic)	•				•		•	
55010U	Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Urine (CSA)	•		•	•			•	
54334U	Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation (Drug Impaired Driving/DRE Toxicology), Urine	•		•	•				
52092U	Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)	•			•	•		•	
52407U	Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)	•		•	•			•	
52448U	Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)	•			•			•	
53092U	Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)	•			•	•		•	
4303U	Talwin® Nx, Urine				•			•	
4490SP	Tolazamide, Serum/Plasma		•	•	•			•	
4500B	Tolbutamide, Blood								•
4500SP	Tolbutamide, Serum/Plasma		•	•	•			•	
4513U	Toluene Exposure, Urine			•				•	
4821U	Xylene Exposure Panel, Urine		•	•	•	•			
1352U	o-Cresol, Urine			•				•	
3100U	t,t-Muconic Acid, Urine			•					

Test Updates

Test Changes

2302U Aromatic Solvent Metabolites Panel 1, Urine

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Scope of Analysis was changed. 2-Methylhippuric Acid, 2-Methylhippuric Acid (Creatinine corrected), 3- and 4-Methylhippuric Acid, 3- and 4-Methylhippuric Acid (Creatinine corrected), Methylhippuric Acids - Total, Methylhippuric Acids - Total (Creatinine corrected) and Mandelic Acid Plus Phenylglyoxylic Acid (Creatinine corrected) were added. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (83921)] Methylhippuric Acid and Methylhippuric Acid (Creatinine corrected) were removed.

Specimen Requirements:	3 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Collect sample at end of shift. Acidify with 1.0 mL acetic acid per 100 mL urine.
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 5 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis:	Colorimetry (82570): Creatinine
Method (CPT Code)	LC-MS/MS (83921): Phenylglyoxylic Acid, Phenylglyoxylic Acid (Creatinine corrected), Mandelic Acid, Mandelic Acid (Creatinine corrected), Mandelic Acid Plus Phenylglyoxylic Acid (Creatinine corrected), Hippuric Acid, Hippuric Acid (Creatinine corrected), 2-Methylhippuric Acid, 2-Methylhippuric Acid (Creatinine corrected), 3- and 4-Methylhippuric Acid, 3- and 4-Methylhippuric Acid (Creatinine corrected), Methylhippuric Acids - Total, Methylhippuric Acids - Total (Creatinine corrected)

Compound Name	Units	Reference Comment
Phenylglyoxylic Acid	g/L	Phenylgloxylic acid is not usually detected in the non-exposed general population.
Phenylglyoxylic Acid (Creatinine corrected)	g/g Creat	[Reference comment removed]
Mandelic Acid	g/L	The detection of significant amounts of mandelic acid in non-occupationally exposed populations is unlikely; however, a background level up to 0.005 g/L has been reported.
Mandelic Acid (Creatinine corrected)	g/g Creat	[Reference comment removed]

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Mandelic Acid Plus Phenylglyoxylic Acid (Creatinine corrected)	g/g Creat	Following exposure to styrene the ACGIH Biological Exposure Index (BEI) for mandelic acid plus phenylglyoxylic acid is 0.4 g/g creatinine measured in an end of shift urine specimen. Following exposure to ethylbenzene the ACGIH Biological Exposure Index (BEI) for mandelic acid plus phenylglyoxylic acid is 0.15 g/g creatinine measured in an end of shift urine specimen.
Hippuric Acid	g/L	Normal for unexposed populations is generally less than 1.6 g/L.
Hippuric Acid (Creatinine corrected)	g/g Creat	Normal for unexposed populations is generally less than 1.5 g/g creatinine.
2-Methylhippuric Acid	g/L	Methylhippuric acids are not usually detected in the non-exposed general population.
2-Methylhippuric Acid (Creatinine corrected)	g/g Creat	
3- and 4-Methylhippuric Acid	g/L	Methylhippuric acids are not usually detected in the non-exposed general population.
3- and 4-Methylhippuric Acid (Creatinine corrected)	g/g Creat	
Methylhippuric Acids - Total	g/L	Methylhippuric acids are usually not detected in the non-exposed general population.
Methylhippuric Acids - Total (Creatinine corrected)	g/g Creat	Following exposure to xylenes, the ACGIH Biological Exposure Index (BEI) for methylhippuric acids is 1.5 g/g creatinine measured in an end of shift urine specimen.

2626B Bath Salts Panel, Blood

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Scope of Analysis was changed.
Order of Reporting was changed.
DMAA was removed.
Mephedrone and Methoxetamine were added.

Test Updates

Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Light Blue top tube (Sodium Citrate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature.
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80371): Methylone, Mephedrone, alpha-PVP, Pentedrone, MDPV, Methoxetamine

2626SP Bath Salts Panel, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Special Handling) were changed. Scope of Analysis was changed. Order of Reporting was changed. DMAA was removed. Mephedrone and Methoxetamine were added.

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Light Blue top tube (Sodium Citrate), Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum is not recommended because the citrate anticoagulant is needed to enhance stability. Plasma: Collect sample in Light Blue top tube (Sodium Citrate) Serum is not recommended because the citrate anticoagulant is needed to enhance stability. Promptly centrifuge and separate Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80371): Methylone, Mephedrone, alpha-PVP, Pentedrone, MDPV, Methoxetamine

2626U Bath Salts Panel, Urine

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. Order of Reporting was changed. DMAA was removed. Mephedrone and Methoxetamine were added.

Test Updates

Test Changes

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 1 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 30 day(s) If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory. NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80371): Methylone, Mephedrone, alpha-PVP, Pentedrone, MDPV, Methoxetamine

3101U Benzene Metabolites Panel, Urine

Summary of Changes:	Specimen Requirements were changed.

Specimen Requirements:	5 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Add 1 drop of 12 N HCl.
Rejection Criteria:	Received Room Temperature.

52167TI Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) Confirmation, Tissue (Forensic)

Summary of Changes:	Test Name was changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed.

Test Updates

Test Changes

Specimen Requirements:	10 g Tissue
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: Undetermined Refrigerated: Undetermined Frozen (-20 °C): Undetermined
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80348): Buprenorphine - Total, Norbuprenorphine - Total

Compound Name	Units	Reference Comment
Buprenorphine - Total	ng/g	The reported result represents the total of free and conjugated buprenorphine.
Norbuprenorphine - Total	ng/g	Buprenorphine is metabolized in the liver by N-dealkylation to inactive norbuprenorphine and both buprenorphine and norbuprenorphine undergo glucuronide conjugation. The reported result represents the total of free and conjugated norbuprenorphine.

53167TI Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) Confirmation, Tissue (Forensic)

Summary of Changes:	Test Name was changed. Specimen Requirements (Specimen Container) were changed. Scope of Analysis was changed. Reference Comment was changed. Buprenorphine - Free and Norbuprenorphine - Free were removed. Buprenorphine - Total and Norbuprenorphine - Total were added.

Specimen Requirements:	10 g Tissue
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80348): Buprenorphine - Total, Norbuprenorphine - Total

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Norbuprenorphine - Total	ng/g	Buprenorphine is metabolized in the liver by N-dealkylation to inactive norbuprenorphine and both buprenorphine and norbuprenorphine undergo glucuronide conjugation. The reported result represents the total of free and conjugated norbuprenorphine.

52264U Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) Confirmation (Qualitative), Urine (CSA)

Summary of Changes: Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80348): Buprenorphine - Total, Norbuprenorphine - Total

Compound Name	Units	Reference Comment
Buprenorphine - Total	ng/mL	The reported result represents the total of free and conjugated buprenorphine.
Norbuprenorphine - Total	ng/mL	Buprenorphine is metabolized in the liver by N-dealkylation to inactive norbuprenorphine and both buprenorphine and norbuprenorphine undergo glucuronide conjugation. The reported result represents the total of free and conjugated norbuprenorphine.

52167U Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 2 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 30 day(s)

Test Updates

Test Changes

Scope of Analysis: Method (CPT Code): LC-MS/MS (80348): Buprenorphine - Total, Norbuprenorphine - Total

Compound Name	Units	Reference Comment
Buprenorphine - Total	ng/mL	The reported result represents the total of free and conjugated buprenorphine.
Norbuprenorphine - Total	ng/mL	Buprenorphine is metabolized in the liver by N-dealkylation to inactive norbuprenorphine and both buprenorphine and norbuprenorphine undergo glucuronide conjugation. The reported result represents the total of free and conjugated norbuprenorphine.

53167U Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)

Summary of Changes: Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80348): Buprenorphine - Total, Norbuprenorphine - Total

Compound Name	Units	Reference Comment
Buprenorphine - Total	ng/mL	The reported result represents the total of free and conjugated buprenorphine.
Norbuprenorphine - Total	ng/mL	Buprenorphine is metabolized in the liver by N-dealkylation to inactive norbuprenorphine and both buprenorphine and norbuprenorphine undergo glucuronide conjugation. The reported result represents the total of free and conjugated norbuprenorphine.

0801U Buprenorphine and Metabolite - Total (Conjugated/Unconjugated), Urine

Test Updates

Test Changes

Summary of Changes: Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80348): Buprenorphine - Total, Norbuprenorphine - Total

Compound Name	Units	Reference Comment
Buprenorphine - Total	ng/mL	The reported result represents the total of free and conjugated buprenorphine.
Norbuprenorphine - Total	ng/mL	Buprenorphine is metabolized in the liver by N-dealkylation to inactive norbuprenorphine and both buprenorphine and norbuprenorphine undergo glucuronide conjugation. The reported result represents the total of free and conjugated norbuprenorphine.

5113U Buprenorphine and Metabolite -Total (Conjugated/Unconjugated) Confirmation, Urine

Summary of Changes: Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80348): Buprenorphine - Total, Norbuprenorphine - Total

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Buprenorphine - Total	ng/mL	The reported result represents the total of free and conjugated buprenorphine.
Norbuprenorphine - Total	ng/mL	Buprenorphine is metabolized in the liver by N-dealkylation to inactive norbuprenorphine and both buprenorphine and norbuprenorphine undergo glucuronide conjugation. The reported result represents the total of free and conjugated norbuprenorphine.

0885U Butorphanol - Total (Conjugated/Unconjugated), Urine

Summary of Changes:
Test Name was changed.
Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80362)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (80362): Butorphanol - Total

Compound Name	Units	Reference Comment
Butorphanol - Total	ng/mL	Free butorphanol may be detected in urine following therapeutic use. The reported result represents the total butorphanol in the sample following hydrolysis.

52019B Chlorpropamide Confirmation, Blood (Forensic)

Summary of Changes:
Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.

Test Updates

Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 28 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 4 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Chlorpropamide

Compound Name	Units	Reference Comment
Chlorpropamide	mcg/mL	Peak plasma concentrations of approximately 75 - 360 mcg/mL were achieved 2 hours following chronic daily doses of 250 - 1000 mg. The blood to plasma ratio of Chlorpropamide is not known.

53019B Chlorpropamide Confirmation, Blood (Forensic)

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 28 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 4 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Chlorpropamide

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Chlorpropamide	mcg/mL	Peak plasma concentrations of approximately 75 - 360 mcg/mL were achieved 2 hours following chronic daily doses of 250 - 1000 mg. The blood to plasma ratio of Chlorpropamide is not known.

52019SP Chlorpropamide Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Stability: Room Temperature: 28 day(s)
Refrigerated: 28 day(s)
Frozen (-20 °C): 30 day(s)

Scope of Analysis: LC-MS/MS (80375): Chlorpropamide
Method (CPT Code)

Compound Name	Units	Reference Comment
Chlorpropamide	mcg/mL	Peak plasma concentrations of approximately 75 - 360 mcg/mL were achieved 2 hours following chronic daily doses of 250 - 1000 mg.

53019SP Chlorpropamide Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Stability: Room Temperature: 28 day(s)
Refrigerated: 28 day(s)
Frozen (-20 °C): 30 day(s)

Scope of Analysis: LC-MS/MS (80375): Chlorpropamide
Method (CPT Code)

Compound Name	Units	Reference Comment
Chlorpropamide	mcg/mL	Peak plasma concentrations of approximately 75 - 360 mcg/mL were achieved 2 hours following chronic daily doses of 250 - 1000 mg.

1220SP Chlorpropamide, Serum/Plasma

Summary of Changes: Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Test Updates

Test Changes

Stability: Room Temperature: 28 day(s)
Refrigerated: 28 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80375): Chlorpropamide
Method (CPT Code)

Compound Name	Units	Reference Comment
Chlorpropamide	mcg/mL	Peak plasma concentrations of approximately 75 - 360 mcg/mL were achieved 2 hours following chronic daily doses of 250 - 1000 mg.

1350U Cresols, Urine

Summary of Changes: Specimen Requirements (Special Handling) were changed.
Reference Comment was changed.

Specimen Requirements: 3 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Collect sample at end of shift.
Samples preserved with Benzoic Acid are unsuitable for analysis. Preservative-free Urine samples are recommended.
Rejection Criteria: None
Scope of Analysis: GC (84600): o-Cresol, p-and/or m-Cresol
Method (CPT Code)

Compound Name	Units	Reference Comment
o-Cresol	mg/L	The mean concentration in the urine of the general population is approximately 0.1 mg o-Cresol/L

1439SP Dantrolene, Serum/Plasma

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Frozen
Specimen Container: Lavender top tube (EDTA)
Light Protection: Yes
Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Not received Light Protected. Received Room Temperature. Received Refrigerated. Polymer gel separation tube (SST or PST).

Test Updates

Test Changes

Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): 7 day(s)

2029U Ethylbenzene Exposure Biouptake, Urine

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Special Handling) were changed.
Scope of Analysis was changed.
Phenylglyoxylic Acid, Phenylglyoxylic Acid (Creatinine corrected) and Mandelic Acid Plus Phenylglyoxylic Acid (Creatinine corrected) were added.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (83921)]

Specimen Requirements: 3 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Collect sample at end of shift.
Acidify with 1.0 mL acetic acid per 100 mL urine.
Rejection Criteria: Received Room Temperature.
Scope of Analysis: Colorimetry (82570): Creatinine
Method (CPT Code) LC-MS/MS (83921): Phenylglyoxylic Acid, Phenylglyoxylic Acid (Creatinine corrected), Mandelic Acid, Mandelic Acid (Creatinine corrected), Mandelic Acid Plus Phenylglyoxylic Acid (Creatinine corrected)

Compound Name	Units	Reference Comment
Phenylglyoxylic Acid	g/L	Phenylgloxylic acid is not usually detected in the non-exposed general population.
Phenylglyoxylic Acid (Creatinine corrected)	g/g Creat	[Reference comment removed]
Mandelic Acid	g/L	The detection of significant amounts of mandelic acid in non-occupationally exposed populations is unlikely; however, a background level up to 0.005 g/L has been reported.
Mandelic Acid (Creatinine corrected)	g/g Creat	[Reference comment removed]
Mandelic Acid Plus Phenylglyoxylic Acid (Creatinine corrected)	g/g Creat	Following exposure to ethylbenzene the ACGIH Biological Exposure Index (BEI) for mandelic acid plus phenylglyoxylic acid is 0.15 g/g creatinine measured in an end of shift urine specimen.

54380B Glimepiride Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic)

Test Updates

Test Changes

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 28 day(s)
Refrigerated: 28 day(s)
Frozen (-20 °C): 28 day(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (83789): Glimepiride

Compound Name	Units	Reference Comment
Glimepiride	ng/mL	Peak plasma concentrations of approximately 60 - 340 ng/mL were achieved 2 - 3 hours after administration of 4 mg of glimepiride. The blood to plasma ratio of Glimepiride is not known.

54380SP Glimepiride Confirmation (Drug Impaired Driving/DRE Toxicology), Serum/Plasma (Forensic)

Summary of Changes: Test Name was changed.
Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 28 day(s)
Refrigerated: 28 day(s)
Frozen (-20 °C): 28 day(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (83789): Glimepiride

Compound Name	Units	Reference Comment
Glimepiride	ng/mL	Peak plasma concentrations of approximately 60 - 340 ng/mL were achieved 2 - 3 hours after administration of 4 mg of glimepiride.

52438B Glimepiride Confirmation, Blood (Forensic)

Test Updates

Test Changes

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 28 day(s)
Refrigerated: 28 day(s)
Frozen (-20 °C): 28 day(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (83789): Glimepiride

Compound Name	Units	Reference Comment
Glimepiride	ng/mL	Peak plasma concentrations of approximately 60 - 340 ng/mL were achieved 2 - 3 hours after administration of 4 mg of glimepiride. The blood to plasma ratio of Glimepiride is not known.

52438SP Glimepiride Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Test Name was changed.
Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 28 day(s)
Refrigerated: 28 day(s)
Frozen (-20 °C): 28 day(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (83789): Glimepiride

Compound Name	Units	Reference Comment
Glimepiride	ng/mL	Peak plasma concentrations of approximately 60 - 340 ng/mL were achieved 2 - 3 hours after administration of 4 mg of glimepiride.

2158SP Glipizide, Serum/Plasma

Test Updates

Test Changes

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate). Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 14 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Glipizide

Compound Name	Units	Reference Comment
Glipizide	ng/mL	Peak plasma concentrations of approximately 310 - 610 ng/mL were achieved after administration of a single 5 mg dose of both immediate and extended release formulations. Maximum concentrations were reached in approximately 1.5 - 4.5 and 3.5 - 7 hours after immediate and extended release dosing, respectively.

2163SP Glyburide, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate). Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 28 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Glyburide

Compound Name	Units	Reference Comment
Glyburide	ng/mL	Peak plasma concentrations of approximately 130 - 200 ng/mL following a single 5 mg dose have been reported. A group of ten diabetic patients given daily oral 2.5 mg doses for 6 weeks attained peak plasma glyburide concentrations averaging 140 ng/mL at 3 hours after the first dose and 240 ng/mL at 2.4 hours after the last dose.

2306U Hippuric Acid and Methylhippuric Acid, Urine

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Special Handling) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Scope of Analysis was changed. 2-Methylhippuric Acid (Creatinine corrected), 3- and 4-Methylhippuric Acid, 3- and 4-Methylhippuric Acid (Creatinine corrected), Methylhippuric Acids - Total, Methylhippuric Acids - Total (Creatinine corrected) and 2-Methylhippuric Acid were added. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (83921)] Methylhippuric Acid and Methylhippuric Acid (Creatinine corrected) were removed.

Test Updates

Test Changes

Specimen Requirements:	3 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Collect sample at end of shift. Acidify with 1.0 mL acetic acid per 100 mL urine.
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 5 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis:	Colorimetry (82570): Creatinine
Method (CPT Code)	LC-MS/MS (83921): Hippuric Acid, Hippuric Acid (Creatinine corrected), 2-Methylhippuric Acid, 2-Methylhippuric Acid (Creatinine corrected), 3- and 4-Methylhippuric Acid, 3- and 4-Methylhippuric Acid (Creatinine corrected), Methylhippuric Acids - Total, Methylhippuric Acids - Total (Creatinine corrected)

Compound Name	Units	Reference Comment
Hippuric Acid	g/L	Normal for unexposed populations is generally less than 1.6 g/L.
Hippuric Acid (Creatinine corrected)	g/g Creat	Normal for unexposed populations is generally less than 1.5 g/g creatinine.
2-Methylhippuric Acid	g/L	Methylhippuric acids are not usually detected in the non-exposed general population.
2-Methylhippuric Acid (Creatinine corrected)	g/g Creat	
3- and 4-Methylhippuric Acid	g/L	Methylhippuric acids are not usually detected in the non-exposed general population.
3- and 4-Methylhippuric Acid (Creatinine corrected)	g/g Creat	
Methylhippuric Acids - Total	g/L	Methylhippuric acids are usually not detected in the non-exposed general population.
Methylhippuric Acids - Total (Creatinine corrected)	g/g Creat	Following exposure to xylenes, the ACGIH Biological Exposure Index (BEI) for methylhippuric acids is 1.5 g/g creatinine measured in an end of shift urine specimen.

2300U Hippuric Acid, Urine

Test Changes

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (83921)]

Specimen Requirements:	3 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Collect sample at end of shift. The acidification of the urine with 1.0 mL acetic acid per 100 mL urine will prolong the stability of the analyte.
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 5 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis:	Colorimetry (82570): Creatinine
Method (CPT Code)	LC-MS/MS (83921): Hippuric Acid, Hippuric Acid (Creatinine corrected)

Compound Name	Units	Reference Comment
Hippuric Acid	g/L	Normal for unexposed populations is generally less than 1.6 g/L.
Hippuric Acid (Creatinine corrected)	g/g Creat	Normal for unexposed populations is generally less than 1.5 g/g creatinine.

4261B Hypoglycemic Panel, Blood

Summary of Changes:	Test Name was changed. Stability was changed. Scope of Analysis was changed. Order of Reporting was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (80377)] Acetohexamide and Tolazamide were removed. Rosiglitazone and Pioglitazone were added.

Stability:	Room Temperature: 14 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 28 day(s)
Scope of Analysis:	LC-MS/MS (80377): Rosiglitazone, Chlorpropamide, Tolbutamide, Glipizide,
Method (CPT Code)	Pioglitazone, Glyburide, Glimepiride, Nateglinide, Repaglinide

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Chlorpropamide	mcg/mL	Peak plasma concentrations of approximately 75 - 360 mcg/mL were achieved 2 hours following chronic daily doses of 250 - 1000 mg. The blood to plasma ratio of Chlorpropamide is not known.
Tolbutamide	mcg/mL	Peak plasma concentrations of approximately 50 - 100 mcg/mL were achieved 3 -5 hours following chronic daily doses. The reported blood to plasma ratio of Tolbutamide is 0.5 - 0.6.
Glipizide	ng/mL	Peak plasma concentrations of approximately 310 - 610 ng/mL were achieved after administration of a single 5 mg dose of both immediate and extended release formulations. Maximum concentrations were reached in approximately 1.5 - 4.5 and 3.5 - 7 hours after immediate and extended release dosing, respectively. The blood to plasma ratio of Glipizide is not known.
Glyburide	ng/mL	Peak plasma concentrations of approximately 130 - 200 ng/mL following a single 5 mg dose have been reported. A group of ten diabetic patients given daily oral 2.5 mg doses for 6 weeks attained peak plasma glyburide concentrations averaging 140 ng/mL at 3 hours after the first dose and 240 ng/mL at 2.4 hours after the last dose. The reported blood to plasma ratio of Glyburide is 0.5.
Glimepiride	ng/mL	Peak plasma concentrations of approximately 60 - 340 ng/mL were achieved 2 - 3 hours after administration of 4 mg of glimepiride. The blood to plasma ratio of Glimepiride is not known.
Nateglinide	mcg/mL	Peak plasma concentrations of approximately 1.3 - 7.5 mcg/mL were achieved 0.5 hours following a single 60 mg dose. The blood to plasma ratio of Nateglinide is not known.

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Repaglinide	ng/mL	Peak plasma concentrations of approximately <10 - 180 ng/mL were achieved 1 hour after administration of 4 mg of repaglinide. The reported blood to plasma ratio of Repaglinide is 0.6 - 0.7.

4261SP Hypoglycemic Panel, Serum/Plasma

Summary of Changes: Test Name was changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (80377)]
Acetohexamide was removed.
Rosiglitazone and Pioglitazone were added.

Stability: Room Temperature: 2 day(s)
Refrigerated: 28 day(s)
Frozen (-20 °C): 28 day(s)

Scope of Analysis: Method (CPT Code): LC-MS/MS (80377): Rosiglitazone, Chlorpropamide, Tolbutamide, Tolazamide, Glipizide, Pioglitazone, Glyburide, Glimepiride, Nateglinide, Repaglinide

Compound Name	Units	Reference Comment
Chlorpropamide	mcg/mL	Peak plasma concentrations of approximately 75 - 360 mcg/mL were achieved 2 hours following chronic daily doses of 250 - 1000 mg.
Tolbutamide	mcg/mL	Peak plasma concentrations of approximately 50 - 100 mcg/mL were achieved 3 -5 hours following chronic daily doses.
Tolazamide	mcg/mL	No plasma concentrations have been reported in the literature
Glipizide	ng/mL	Peak plasma concentrations of approximately 310 - 610 ng/mL were achieved after administration of a single 5 mg dose of both immediate and extended release formulations. Maximum concentrations were reached in approximately 1.5 - 4.5 and 3.5 - 7 hours after immediate and extended release dosing, respectively.

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Glyburide	ng/mL	Peak plasma concentrations of approximately 130 - 200 ng/mL following a single 5 mg dose have been reported. A group of ten diabetic patients given daily oral 2.5 mg doses for 6 weeks attained peak plasma glyburide concentrations averaging 140 ng/mL at 3 hours after the first dose and 240 ng/mL at 2.4 hours after the last dose.
Glimepiride	ng/mL	Peak plasma concentrations of approximately 60 - 340 ng/mL were achieved 2 - 3 hours after administration of 4 mg of glimepiride.
Nateglinide	mcg/mL	Peak plasma concentrations of approximately 1.3 - 7.5 mcg/mL were achieved 0.5 hours following a single 60 mg dose.
Repaglinide	ng/mL	Peak plasma concentrations of approximately <10 - 180 ng/mL were achieved 1 hour after administration of 4 mg of repaglinide.

54331B Hypoglycemics Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic)

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 4 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Glipizide, Glyburide

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Glipizide	ng/mL	Peak plasma concentrations of approximately 310 - 610 ng/mL were achieved after administration of a single 5 mg dose of both immediate and extended release formulations. Maximum concentrations were reached in approximately 1.5 - 4.5 and 3.5 - 7 hours after immediate and extended release dosing, respectively. The blood to plasma ratio of Glipizide is not known.
Glyburide	ng/mL	Peak plasma concentrations of approximately 130 - 200 ng/mL following a single 5 mg dose have been reported. A group of ten diabetic patients given daily oral 2.5 mg doses for 6 weeks attained peak plasma glyburide concentrations averaging 140 ng/mL at 3 hours after the first dose and 240 ng/mL at 2.4 hours after the last dose. The reported blood to plasma ratio of Glyburide is 0.5.

54331SP Hypoglycemics Confirmation (Drug Impaired Driving/DRE Toxicology), Serum/Plasma (Forensic)

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]
Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate). Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 14 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Glipizide, Glyburide

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Glipizide	ng/mL	Peak plasma concentrations of approximately 310 - 610 ng/mL were achieved after administration of a single 5 mg dose of both immediate and extended release formulations. Maximum concentrations were reached in approximately 1.5 - 4.5 and 3.5 - 7 hours after immediate and extended release dosing, respectively.
Glyburide	ng/mL	Peak plasma concentrations of approximately 130 - 200 ng/mL following a single 5 mg dose have been reported. A group of ten diabetic patients given daily oral 2.5 mg doses for 6 weeks attained peak plasma glyburide concentrations averaging 140 ng/mL at 3 hours after the first dose and 240 ng/mL at 2.4 hours after the last dose.

52405B Hypoglycemics Confirmation, Blood (Forensic)

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 28 day(s)
Frozen (-20 °C): 4 month(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (80375): Glipizide, Glyburide

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Glipizide	ng/mL	Peak plasma concentrations of approximately 310 - 610 ng/mL were achieved after administration of a single 5 mg dose of both immediate and extended release formulations. Maximum concentrations were reached in approximately 1.5 - 4.5 and 3.5 - 7 hours after immediate and extended release dosing, respectively. The blood to plasma ratio of Glipizide is not known.
Glyburide	ng/mL	Peak plasma concentrations of approximately 130 - 200 ng/mL following a single 5 mg dose have been reported. A group of ten diabetic patients given daily oral 2.5 mg doses for 6 weeks attained peak plasma glyburide concentrations averaging 140 ng/mL at 3 hours after the first dose and 240 ng/mL at 2.4 hours after the last dose. The reported blood to plasma ratio of Glyburide is 0.5.

52405SP Hypoglycemics Confirmation, Serum/Plasma (Forensic)

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]
Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate). Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 14 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Glipizide, Glyburide

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Glipizide	ng/mL	Peak plasma concentrations of approximately 310 - 610 ng/mL were achieved after administration of a single 5 mg dose of both immediate and extended release formulations. Maximum concentrations were reached in approximately 1.5 - 4.5 and 3.5 - 7 hours after immediate and extended release dosing, respectively.
Glyburide	ng/mL	Peak plasma concentrations of approximately 130 - 200 ng/mL following a single 5 mg dose have been reported. A group of ten diabetic patients given daily oral 2.5 mg doses for 6 weeks attained peak plasma glyburide concentrations averaging 140 ng/mL at 3 hours after the first dose and 240 ng/mL at 2.4 hours after the last dose.

2416U Inhalants Metabolites Panel, Urine

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Special Handling) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
o-Cresol (Creatinine corrected), Mandelic Acid (Creatinine corrected), Phenol - Total (Creatinine corrected), Mandelic Acid Plus Phenylglyoxylic Acid (Creatinine corrected), Hippuric Acid (Creatinine corrected), 2-Methylhippuric Acid, 2-Methylhippuric Acid (Creatinine corrected), 3- and 4-Methylhippuric Acid, 3- and 4-Methylhippuric Acid (Creatinine corrected), Methylhippuric Acids - Total, Methylhippuric Acids - Total (Creatinine corrected) and Phenylglyoxylic Acid (Creatinine corrected) were added.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (83921)]
Trichloroacetic Acid and Methylhippuric Acid were removed.

Specimen Requirements: 5 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Collect sample at end of shift.
Acidify with 1.0 mL acetic acid per 100 mL urine.
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 4 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 14 day(s)

Test Updates

Test Changes

Scope of Analysis: Method (CPT Code)
GC (84600): o-Cresol, o-Cresol (Creatinine corrected), Phenol - Total, Phenol - Total (Creatinine corrected)
LC-MS/MS (83921): Phenylglyoxylic Acid, Phenylglyoxylic Acid (Creatinine corrected), Mandelic Acid, Mandelic Acid (Creatinine corrected), Mandelic Acid Plus Phenylglyoxylic Acid (Creatinine corrected), Hippuric Acid, Hippuric Acid (Creatinine corrected), 2-Methylhippuric Acid, 2-Methylhippuric Acid (Creatinine corrected), 3- and 4-Methylhippuric Acid, 3- and 4-Methylhippuric Acid (Creatinine corrected), Methylhippuric Acids - Total, Methylhippuric Acids - Total (Creatinine corrected)
Colorimetry (82570): Creatinine

Compound Name	Units	Reference Comment
Phenylglyoxylic Acid	g/L	Phenylgloxylic acid is not usually detected in the non-exposed general population.
o-Cresol	mg/L	The mean concentration in the urine of the general population is approximately 0.1 mg o-Cresol/L
Phenylglyoxylic Acid (Creatinine corrected)	g/g Creat	
o-Cresol (Creatinine corrected)	mg/g Creat	Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 0.3 mg o-Cresol/g Creatinine measured in an end of shift urine specimen.
Mandelic Acid	g/L	The detection of significant amounts of mandelic acid in non-occupationally exposed populations is unlikely; however, a background level up to 0.005 g/L has been reported.
Phenol - Total	mg/L	Less than 10 mg/L in unexposed individuals. Less than 30 mg/L when chronically exposed to 0.5 to 4.0 ppm Benzene in air. Average 200 mg/L during chronic exposure to 25 ppm Benzene in air.
Mandelic Acid (Creatinine corrected)	g/g Creat	
Phenol - Total (Creatinine corrected)	mg/g Creat	Biological Exposure Index (ACGIH): 250 mg Phenol/g Creatinine measured in an end of shift urine.
Mandelic Acid Plus Phenylglyoxylic Acid (Creatinine corrected)	g/g Creat	Following exposure to styrene the ACGIH Biological Exposure Index (BEI) for mandelic acid plus phenylglyoxylic acid is 0.4 g/g creatinine measured in an end of shift urine specimen. Following exposure to ethylbenzene the ACGIH Biological Exposure Index (BEI) for mandelic acid plus phenylglyoxylic acid is 0.15 g/g creatinine measured in an end of shift urine specimen.

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Hippuric Acid	g/L	Normal for unexposed populations is generally less than 1.6 g/L.
Hippuric Acid (Creatinine corrected)	g/g Creat	Normal for unexposed populations is generally less than 1.5 g/g creatinine.
2-Methylhippuric Acid	g/L	Methylhippuric acids are not usually detected in the non-exposed general population.
2-Methylhippuric Acid (Creatinine corrected)	g/g Creat	
3- and 4-Methylhippuric Acid	g/L	Methylhippuric acids are not usually detected in the non-exposed general population.
3- and 4-Methylhippuric Acid (Creatinine corrected)	g/g Creat	
Methylhippuric Acids - Total	g/L	Methylhippuric acids are usually not detected in the non-exposed general population.
Methylhippuric Acids - Total (Creatinine corrected)	g/g Creat	Following exposure to xylenes, the ACGIH Biological Exposure Index (BEI) for methylhippuric acids is 1.5 g/g creatinine measured in an end of shift urine specimen.

2505SP Levetiracetam, Serum/Plasma

Summary of Changes: Stability was changed.

Stability:
Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 3 month(s)

2837SP Methanol Poisoning Profile, Serum/Plasma

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Test Updates

Test Changes

Specimen Requirements:	2 mL Serum or Plasma
Transport Temperature:	Frozen
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Collect sample using alcohol free skin preparation. Promptly centrifuge and separate Serum or Plasma into an plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Received Refrigerated. Gray top tube (Sodium Fluoride / Potassium Oxalate). Polymer gel separation tube (SST or PST).

3110U Nalbuphine - Total (Conjugated/Unconjugated), Urine

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80362)]

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80362): Nalbuphine - Total

Compound Name	Units	Reference Comment
Nalbuphine - Total	ng/mL	The reported result represents the total of free and conjugated nalbuphine.

5119U Naloxone - Total (Conjugated/Unconjugated) Confirmation, Urine

Summary of Changes:	Stability was changed. Reference Comment was changed.

Stability:	Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80362): Naloxone - Total

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Naloxone - Total	ng/mL	The reported result represents the total of free and conjugated naloxone.

3113U Naloxone - Total (Conjugated/Unconjugated) Screen, Urine

Summary of Changes: Specimen Requirements were changed.
Stability was changed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

3111U Naloxone - Total (Conjugated/Unconjugated), Urine

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80362): Naloxone - Total
Method (CPT Code)

Compound Name	Units	Reference Comment
Naloxone - Total	ng/mL	The reported result represents the total of free and conjugated naloxone.

52449U Naltrexone - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80362): Naltrexone - Total
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Naltrexone - Total	ng/mL	The reported result represents the total of free and conjugated naltrexone.

3116U Naltrexone and Metabolite - Total (Conjugated/Unconjugated), Urine

Summary of Changes:
Stability was changed.
Reference Comment was changed.

Stability:
Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Scope of Analysis: Method (CPT Code):
LC-MS/MS (80362): Naltrexone - Total, 6-Beta-Naltrexol - Total

Compound Name	Units	Reference Comment
Naltrexone - Total	ng/mL	The reported result represents the total of free and conjugated naltrexone.
6-Beta-Naltrexol - Total	ng/mL	6-beta naltrexol is the major metabolite of naltrexone that is excreted in urine. Approximately 30% is conjugated. The reported result represents the total of free and conjugated 6-beta-naltrexol.

4213U Styrene Exposure Profile, Urine

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
Mandelic Acid Plus Phenylglyoxylic Acid (Creatinine corrected) was added.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (83921)]

Specimen Requirements: 3 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Collect sample at end of shift.
Acidify with 1.0 mL acetic acid per 100 mL urine.
Rejection Criteria: Received Room Temperature.

Test Updates

Test Changes

Stability:	Room Temperature: 5 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83921): Phenylglyoxylic Acid, Phenylglyoxylic Acid (Creatinine corrected), Mandelic Acid, Mandelic Acid (Creatinine corrected), Mandelic Acid Plus Phenylglyoxylic Acid (Creatinine corrected) Colorimetry (82570): Creatinine

Compound Name	Units	Reference Comment
Phenylglyoxylic Acid	g/L	Phenylgloxylic acid is not usually detected in the non-exposed general population.
Phenylglyoxylic Acid (Creatinine corrected)	g/g Creat	[Reference comment removed]
Mandelic Acid	g/L	The detection of significant amounts of mandelic acid in non-occupationally exposed populations is unlikely; however, a background level up to 0.005 g/L has been reported.
Mandelic Acid (Creatinine corrected)	g/g Creat	[Reference comment removed]
Mandelic Acid Plus Phenylglyoxylic Acid (Creatinine corrected)	g/g Creat	Following exposure to styrene the ACGIH Biological Exposure Index (BEI) for mandelic acid plus phenylglyoxylic acid is 0.4 g/g creatinine measured in an end of shift urine specimen.

4127U Suboxone® - Total, Urine

Summary of Changes:	Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Reference Comment was changed.

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 2 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80348, 80362): Buprenorphine - Total, Norbuprenorphine - Total, Naloxone - Total

Compound Name	Units	Reference Comment
Buprenorphine - Total	ng/mL	The reported result represents the total of free and conjugated buprenorphine.

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Norbuprenorphine - Total	ng/mL	Buprenorphine is metabolized in the liver by N-dealkylation to inactive norbuprenorphine and both buprenorphine and norbuprenorphine undergo glucuronide conjugation. The reported result represents the total of free and conjugated norbuprenorphine.
Naloxone - Total	ng/mL	The reported result represents the total of free and conjugated naloxone.

52092TI Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Tissue (Forensic)

Summary of Changes:
Test Name was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Morphine - Free, Hydromorphone - Free, Nalbuphine - Free, Naloxone - Free, Naltrexone - Free and Butorphanol - Free were removed.
Naltrexone - Total and Butorphanol - Total were added.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80362): Naltrexone - Total, Butorphanol - Total

Compound Name	Units	Reference Comment
Naltrexone - Total	ng/g	The reported result represents the total of free and conjugated naltrexone.
Butorphanol - Total	ng/g	Free butorphanol may be detected in urine following therapeutic use. The reported result represents the total butorphanol in the sample following hydrolysis.

53092TI Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Tissue (Forensic)

Summary of Changes:
Test Name was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Naltrexone - Free, Butorphanol - Free, Morphine - Free, Hydromorphone - Free, Nalbuphine - Free and Naloxone - Free were removed.
Naltrexone - Total and Butorphanol - Total were added.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80362): Naltrexone - Total, Butorphanol - Total

Compound Name	Units	Reference Comment
Naltrexone - Total	ng/g	The reported result represents the total of free and conjugated naltrexone.

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Butorphanol - Total	ng/g	Free butorphanol may be detected in urine following therapeutic use. The reported result represents the total butorphanol in the sample following hydrolysis.

55010U Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Urine (CSA)

Summary of Changes: Test Name was changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80348, 80362): Buprenorphine - Total, Norbuprenorphine - Total,
Method (CPT Code) Butorphanol - Total, Nalbuphine - Total

Compound Name	Units	Reference Comment
Buprenorphine - Total	ng/mL	The reported result represents the total of free and conjugated buprenorphine.
Norbuprenorphine - Total	ng/mL	Buprenorphine is metabolized in the liver by N-dealkylation to inactive norbuprenorphine and both buprenorphine and norbuprenorphine undergo glucuronide conjugation. The reported result represents the total of free and conjugated norbuprenorphine.

54334U Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation (Drug Impaired Driving/DRE Toxicology), Urine

Summary of Changes: Test Name was changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Test Updates

Test Changes

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 2 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 30 day(s)

52092U Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)

Summary of Changes:	Test Name was changed. Stability was changed. Scope of Analysis was changed. Order of Reporting was changed. Reference Comment was changed. Morphine - Total, Hydromorphone - Total, Nalbuphine - Total and Naloxone - Total were removed.
Stability:	Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80362): Naltrexone - Total, Butorphanol - Total

Compound Name	Units	Reference Comment
Naltrexone - Total	ng/mL	The reported result represents the total of free and conjugated naltrexone.
Butorphanol - Total	ng/mL	Free butorphanol may be detected in urine following therapeutic use. The reported result represents the total butorphanol in the sample following hydrolysis.

52407U Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)

Summary of Changes:	Test Name was changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Reference Comment was changed.

Test Updates

Test Changes

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 2 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80348, 80362): Buprenorphine - Total, Norbuprenorphine - Total, Butorphanol - Total, Nalbuphine - Total

Compound Name	Units	Reference Comment
Buprenorphine - Total	ng/mL	The reported result represents the total of free and conjugated buprenorphine.
Norbuprenorphine - Total	ng/mL	Buprenorphine is metabolized in the liver by N-dealkylation to inactive norbuprenorphine and both buprenorphine and norbuprenorphine undergo glucuronide conjugation. The reported result represents the total of free and conjugated norbuprenorphine.
Butorphanol - Total	ng/mL	Free butorphanol may be detected in urine following therapeutic use. The reported result represents the total butorphanol in the sample following hydrolysis.
Nalbuphine - Total	ng/mL	The reported result represents the total of free and conjugated nalbuphine.

52448U Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)

Summary of Changes:	Test Name was changed. Stability was changed. Reference Comment was changed.
Stability:	Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80362): Butorphanol - Total, Nalbuphine - Total

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Butorphanol - Total	ng/mL	Free butorphanol may be detected in urine following therapeutic use. The reported result represents the total butorphanol in the sample following hydrolysis.
Nalbuphine - Total	ng/mL	The reported result represents the total of free and conjugated nalbuphine.

53092U Synthetic Opioids - Total (Conjugated/Unconjugated) Confirmation, Urine (Forensic)

Summary of Changes: Test Name was changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Morphine - Total, Hydromorphone - Total, Nalbuphine - Total and Naloxone - Total were removed.

Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Scope of Analysis: LC-MS/MS (80362): Naltrexone - Total, Butorphanol - Total

Method (CPT Code)

Compound Name	Units	Reference Comment
Naltrexone - Total	ng/mL	The reported result represents the total of free and conjugated naltrexone.
Butorphanol - Total	ng/mL	Free butorphanol may be detected in urine following therapeutic use. The reported result represents the total butorphanol in the sample following hydrolysis.

4303U Talwin® Nx, Urine

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: Undetermined
Refrigerated: Undetermined
Frozen (-20 °C): 30 day(s)

Scope of Analysis: LC-MS/MS (80362): Naloxone - Total

Method (CPT Code) GC (80362): Pentazocine - Total

Compound Name	Units	Reference Comment
Naloxone - Total	ng/mL	The reported result represents the total of free and conjugated naloxone.

Test Updates

Test Changes

4490SP Tolazamide, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate). Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 2 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Tolazamide

Compound Name	Units	Reference Comment
Tolazamide	mcg/mL	No plasma concentrations have been reported in the literature

4500SP Tolbutamide, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate). Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 7 day(s) Refrigerated: 28 day(s) Frozen (-20 °C): 30 day(s)

Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80375): Tolbutamide
Method (CPT Code)

Compound Name	Units	Reference Comment
Tolbutamide	mcg/mL	Peak plasma concentrations of approximately 50 - 100 mcg/mL were achieved 3 -5 hours following chronic daily doses.

4513U Toluene Exposure, Urine

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Special Handling) were changed.
Reference Comment was changed.

Specimen Requirements: 4 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Collect sample at end of shift.
Samples preserved with Benzoic Acid are unsuitable for analysis. Preservative-free Urine samples are recommended.
Rejection Criteria: Received Room Temperature.
Scope of Analysis: Colorimetry (82570): Creatinine
Method (CPT Code) GC (84600): o-Cresol, o-Cresol (Creatinine Corrected)

Compound Name	Units	Reference Comment
o-Cresol	mg/L	The mean concentration in the urine of the general population is approximately 0.1 mg o-Cresol/L
o-Cresol (Creatinine Corrected)	mg/g Creat	Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 0.3 mg o-Cresol/g Creatinine measured in an end of shift urine specimen.

4821U Xylene Exposure Panel, Urine

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Special Handling) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
2-Methylhippuric Acid (Creatinine corrected), 3- and 4-Methylhippuric Acid, 3- and 4-Methylhippuric Acid (Creatinine corrected), Methylhippuric Acids - Total, Methylhippuric Acids - Total (Creatinine corrected) and 2-Methylhippuric Acid were added.
Methods/CPT Codes were changed [LC-MS/MS (83921)]
Methylhippuric Acid and Methylhippuric Acid (Creatinine corrected) were removed.

Test Updates

Test Changes

Specimen Requirements:	3 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Collect sample at end of shift. Acidify with 1.0 mL acetic acid per 100 mL urine.
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 5 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis:	Colorimetry (82570): Creatinine
Method (CPT Code)	LC-MS/MS (83921): 2-Methylhippuric Acid, 2-Methylhippuric Acid (Creatinine corrected), 3- and 4-Methylhippuric Acid, 3- and 4-Methylhippuric Acid (Creatinine corrected), Methylhippuric Acids - Total, Methylhippuric Acids - Total (Creatinine corrected)

Compound Name	Units	Reference Comment
2-Methylhippuric Acid	g/L	Methylhippuric acids are not usually detected in the non-exposed general population.
2-Methylhippuric Acid (Creatinine corrected)	g/g Creat	
3- and 4-Methylhippuric Acid	g/L	Methylhippuric acids are not usually detected in the non-exposed general population.
3- and 4-Methylhippuric Acid (Creatinine corrected)	g/g Creat	
Methylhippuric Acids - Total	g/L	Methylhippuric acids are usually not detected in the non-exposed general population.
Methylhippuric Acids - Total (Creatinine corrected)	g/g Creat	Following exposure to xylenes, the ACGIH Biological Exposure Index (BEI) for methylhippuric acids is 1.5 g/g creatinine measured in an end of shift urine specimen.

1352U o-Cresol, Urine

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Special Handling) were changed. Reference Comment was changed.

Test Updates

Test Changes

Specimen Requirements:	4 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Collect sample at end of shift. Samples preserved with Benzoic Acid are unsuitable for analysis. Preservative-free Urine samples are recommended.
Rejection Criteria:	Received Room Temperature.
Scope of Analysis:	GC (84600): o-Cresol, o-Cresol (Creatinine corrected)
Method (CPT Code)	Colorimetry (82570): Creatinine

Compound Name	Units	Reference Comment
o-Cresol	mg/L	The mean concentration in the urine of the general population is approximately 0.1 mg o-Cresol/L
o-Cresol (Creatinine corrected)	mg/g Creat	Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 0.3 mg o-Cresol/g Creatinine measured in an end of shift urine specimen.

3100U t,t-Muconic Acid, Urine

Summary of Changes:	Specimen Requirements were changed.

Specimen Requirements:	5 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Add 1 drop of 12 N HCl.
Rejection Criteria:	Received Room Temperature.

Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
0070SP	Acetohexamide, Serum/Plasma	No Alternate Tests Available
0457U	Aromatic Solvents Panel, Urine	0430U - Aromatic Solvents Metabolites Panel 2, Urine 2302U - Aromatic Solvent Metabolites Panel 1, Urine
1220B	Chlorpropamide, Blood	1220SP - Chlorpropamide, Serum/Plasma
1220U	Chlorpropamide, Urine	1220SP - Chlorpropamide, Serum/Plasma
2158B	Glipizide, Blood	2158SP - Glipizide, Serum/Plasma
2158U	Glipizide, Urine	2158SP - Glipizide, Serum/Plasma
2163B	Glyburide, Blood	2163SP - Glyburide, Serum/Plasma
2409U	Inhalants Panel, Urine (CSA)	2321U - Hydrocarbon and Oxygenated Volatiles Panel, Urine 2302U - Aromatic Solvent Metabolites Panel 1, Urine 3621U - Phenol Exposure, Urine 1352U - o-Cresol, Urine 0850U - Butanols, n-, iso-, Sec- and Tert, Urine
2426U	Inhalants and Metabolites Panel, Urine	2416U - Inhalants Metabolites Panel, Urine 2411U - Inhalants Panel, Solvents, Urine 4624U - Trichloroacetic Acid, Urine
2994U	Methylhippuric Acid, Urine	4821U - Xylene Exposure Panel, Urine
0872U	Solvent Profile, Urine	0430U - Aromatic Solvents Metabolites Panel 2, Urine 2302U - Aromatic Solvent Metabolites Panel 1, Urine 4624U - Trichloroacetic Acid, Urine 3006U - Methylchloroform, Urine
4500B	Tolbutamide, Blood	4500SP - Tolbutamide, Serum/Plasma